Herceptin eradicates tumours and may reduce the need for mastectomies in women with inflammatory HER2-positive breast cancer – one of the most aggressive and fastest growing forms of the disease New ...

Patients with HER2-positive metastatic breast cancer may receive sufficient first-line treatment with Perjeta plus Herceptin without chemotherapy. The treatment combination of Perjeta (pertuzumab) ...

First targeted medicine shown to improve overall survival in HER2-positive stomach and gastroesophageal junction cancers Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the U.S. Food and Drug ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced the Phase III FeDeriCa study met its primary endpoint. The study ...

Roche today announced results from a major international study which show that adding Herceptin (trastuzumab) to standard chemotherapy significantly prolongs lives of patients with HER2-positive ...

The FDA will allow Herceptin, a biological cancer drug, to be used to treat an aggressive type of breast cancer after surgery. According to the FDA decision, announced yesterday, Herceptin may now be ...

Using Herceptin with chemotherapy, instead of after, clearly improves treatment of women with HER2+ breast cancer, and should be the new standard of care, says a researcher. Using Herceptin with ...

Two recent studies offer hope of enhancing both the effectiveness and safety of Herceptin, the drug that helped introduce the era of targeted therapy. Two studies presented Saturday offer hope of ...

When you or a loved one has breast cancer, your doctor will figure out the best treatment options to offer you based on your particular tumor, your age, other conditions you have, and your wishes.

— Fixed-dose combination administered under the skin in just minutes, compared to hours with intravenous administration, significantly reducing time spent receiving treatment — — Phase III FeDeriCa ...